{"id":50801,"date":"2022-11-14T13:02:22","date_gmt":"2022-11-14T12:02:22","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/"},"modified":"2022-11-14T13:02:22","modified_gmt":"2022-11-14T12:02:22","slug":"exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/","title":{"rendered":"Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments"},"content":{"rendered":"
\n

\nEffort aligns MD Anderson\u2019s drug development expertise with Exscientia\u2019s AI-driven patient-first precision medicine and drug discovery platforms<\/i>\n<\/p>\n

OXFORD, England & HOUSTON, Texas–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center<\/a> today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and development expertise of MD Anderson in order to advance novel small-molecule oncology therapies.\n<\/p>\n

<\/a><\/p>\n

\nThe research collaboration will utilise Exscientia\u2019s precision medicine platform to identify novel anti-cancer, cell-intrinsic small-molecule compounds based on jointly identified therapeutic targets. Promising candidates will advance for further development with the team at MD Anderson\u2019s Therapeutics Discovery division<\/a>. The collaborators anticipate that successful target discovery programs may be advanced into proof-of-concept clinical trials at MD Anderson.\n<\/p>\n

\n\u201cWe are driven to develop the next generation of oncology treatments that can offer meaningful benefits and improve the lives of our patients,\u201d said Philip Jones, Ph.D., vice president of Therapeutics Discovery and head of the Institute for Applied Cancer Science<\/a> (IACS) at MD Anderson. \u201cThis collaboration is built upon Exscientia\u2019s AI-driven precision medicine platform, the strength of MD Anderson\u2019s drug discovery and development engine, and the expertise of our clinical research teams. Our ultimate goal is to decrease the time we spend in drug development and accelerate novel targeted therapies into the clinic.\u201d\n<\/p>\n

\nExscientia will collaborate with the team at IACS, a drug discovery engine focused on developing novel small-molecule therapeutics. IACS is a core component of MD Anderson\u2019s Therapeutics Discovery division, an integrated team of researchers, physicians and drug development experts working to advance impactful new therapies.\n<\/p>\n

\n\u201cWe are tremendously proud to work alongside MD Anderson to harness our AI-driven platform toward the discovery of next-generation cancer treatments. Artificial intelligence has opened up new possibilities in cancer research, enabling us to use deep learning multi-omics within our precision medicine platform to test potential drug candidates in Exscientia\u2019s patient tissue models,\u201d said Professor Andrew Hopkins, D.Phil., founder and Chief Executive Officer of Exscientia. \u201cFurther, our platform holds the potential to stratify patients even in the early discovery stage, allowing us to efficiently design drug candidates that are most likely to be impactful for people with cancer.\u201d\n<\/p>\n

\nUnder the agreement terms, Exscientia and MD Anderson will jointly contribute to and support each program designated to move forward.\n<\/p>\n

\nDisclosure
\n
<\/b>MD Anderson has an institutional conflict of interest with Exscientia, and this relationship will be managed according to an MD Anderson Institutional Conflict of Interest Management and Monitoring Plan.\n<\/p>\n

\nAbout Exscientia
\n
<\/b>Exscientia is an AI-driven pharmatech company committed to discovering, designing and developing the best possible drugs in the fastest and most effective manner. Exscientia developed the first-ever functional precision oncology platform to successfully guide treatment selection and improve patient outcomes in a prospective interventional clinical study, as well as to progress AI-designed small molecules into the clinical setting. Our internal pipeline is focused on leveraging our precision medicine platform in oncology, while our partnered pipeline broadens our approach to other therapeutic areas. By pioneering a new approach to medicine creation, we believe the best ideas of science can rapidly become the best medicines for patients.\n<\/p>\n

\nExscientia is headquartered in Oxford (England, U.K.), with offices in Vienna (Austria), Dundee (Scotland, U.K.), Boston (Mass., U.S.), Miami (Fla., U.S.), Cambridge (England, U.K.), and Osaka (Japan).\n<\/p>\n

\nVisit us at https:\/\/www.exscientia.ai<\/a> or follow us on Twitter @exscientiaAI<\/a>.\n<\/p>\n

\nAbout MD Anderson
\n
<\/b>The University of Texas MD Anderson Cancer Center<\/a> in Houston ranks as one of the world’s most respected centers focused on cancer patient care, research, education and prevention. The institution\u2019s sole mission is to end cancer for patients and their families around the world. MD Anderson is one of only 53 comprehensive cancer centers designated by the National Cancer Institute (NCI). MD Anderson is No. 1 for cancer in U.S. News & World Report\u2019s \u201cBest Hospitals\u201d rankings and has been named one of the nation\u2019s top two hospitals for cancer since the rankings began in 1990. MD Anderson receives a cancer center support grant from the NCI of the National Institutes of Health (P30 CA016672).\n<\/p>\n

\nExscientia Forward-Looking Statements
\n
<\/b>This press release contains forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995, including with respect to the progress of discovery and development of candidate molecules, and the timing and progress of, and data reported from, clinical trials of Exscientia\u2019s product candidates, and Exscientia\u2019s expectations regarding its projected revenue and cash runway. Any statement describing Exscientia\u2019s goals, plans, expectations, financial or other projections, intentions or beliefs is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to a number of risks, uncertainties and assumptions, including those related to: the impact that the COVID-19 pandemic could have on the Company\u2019s business, including the scope, progress and expansion of Exscientia\u2019s product development efforts; the initiation, scope and progress of Exscientia\u2019s and its partners\u2019 planned and ongoing pre-clinical studies and clinical trials and ramifications for the cost thereof; clinical, scientific, regulatory and technical developments; the process of discovering, developing and commercialising product candidates that are safe and effective for use as human therapeutics; and the endeavour of building a business around such product candidates. In light of these risks and uncertainties, and other risks and uncertainties that are described in the Risk Factors section and other sections of Exscientia\u2019s Annual Report on Form 20-F, filed with the Securities and Exchange Commission (SEC) on March 23, 2022 (File No. 001-40850), and other filings that Exscientia makes with the SEC from time to time (which are available at https:\/\/www.sec.gov\/), the events and circumstances discussed in such forward-looking statements may not occur, and Exscientia\u2019s actual results could differ materially and adversely from those anticipated or implied thereby. Although Exscientia\u2019s forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by the Company. As a result, you are cautioned not to rely on these forward-looking statements.\n<\/p>\n

Contacts<\/b> <\/p>\n

\nExscientia Investor Relations Contact<\/b>
Sara Sherman
\n
investors@exscientia.ai<\/a>\n<\/p>\n

\nExscientia Media Contact:<\/b>
media@exscientia.ai<\/a>\n<\/p>\n

\nMD Anderson Media Relations Contact<\/b>
Clayton Boldt, Ph.D.
\n
CRBoldt@MDAnderson.org<\/a>
Phone: 713-792-9518\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

Effort aligns MD Anderson\u2019s drug development expertise with Exscientia\u2019s AI-driven patient-first precision medicine and drug discovery platforms OXFORD, England & HOUSTON, Texas–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-50801","6":"format-standard","7":"category-industry"},"yoast_head":"\nExscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"Effort aligns MD Anderson\u2019s drug development expertise with Exscientia\u2019s AI-driven patient-first precision medicine and drug discovery platforms OXFORD, England & HOUSTON, Texas–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2022-11-14T12:02:22+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20221114005209\/en\/1634873\/21\/Exscientia_logo-01.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments\",\"datePublished\":\"2022-11-14T12:02:22+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\\\/\"},\"wordCount\":1065,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221114005209\\\/en\\\/1634873\\\/21\\\/Exscientia_logo-01.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\\\/\",\"name\":\"Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221114005209\\\/en\\\/1634873\\\/21\\\/Exscientia_logo-01.jpg\",\"datePublished\":\"2022-11-14T12:02:22+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221114005209\\\/en\\\/1634873\\\/21\\\/Exscientia_logo-01.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20221114005209\\\/en\\\/1634873\\\/21\\\/Exscientia_logo-01.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/","og_locale":"en_US","og_type":"article","og_title":"Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments - Pharma Trend","og_description":"Effort aligns MD Anderson\u2019s drug development expertise with Exscientia\u2019s AI-driven patient-first precision medicine and drug discovery platforms OXFORD, England & HOUSTON, Texas–(BUSINESS WIRE)–Exscientia plc (Nasdaq: EXAI) and The University of Texas MD Anderson Cancer Center today announced a strategic collaboration to align the patient-centric artificial intelligence (AI) capabilities of Exscientia with the drug discovery and ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/","og_site_name":"Pharma Trend","article_published_time":"2022-11-14T12:02:22+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20221114005209\/en\/1634873\/21\/Exscientia_logo-01.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments","datePublished":"2022-11-14T12:02:22+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/"},"wordCount":1065,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221114005209\/en\/1634873\/21\/Exscientia_logo-01.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/","url":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/","name":"Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20221114005209\/en\/1634873\/21\/Exscientia_logo-01.jpg","datePublished":"2022-11-14T12:02:22+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20221114005209\/en\/1634873\/21\/Exscientia_logo-01.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20221114005209\/en\/1634873\/21\/Exscientia_logo-01.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/exscientia-and-md-anderson-launch-strategic-collaboration-to-leverage-ai-in-developing-novel-oncology-treatments\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Exscientia and MD Anderson Launch Strategic Collaboration to Leverage AI in Developing Novel Oncology Treatments"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50801","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=50801"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/50801\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=50801"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=50801"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=50801"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}